AVGR - Avinger, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8847
-0.0403 (-4.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9250
Open0.9200
Bid0.8800 x 1100
Ask0.8990 x 3000
Day's Range0.8500 - 0.9280
52 Week Range0.1800 - 2.4400
Volume3,469,191
Avg. Volume3,771,972
Market Cap42.58M
Beta (3Y Monthly)2.74
PE Ratio (TTM)N/A
EPS (TTM)-3.3400
Earnings DateMay 2, 2018 - May 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents12 days ago

    Edited Transcript of AVGR earnings conference call or presentation 6-Mar-19 9:30pm GMT

    Q4 2018 Avinger Inc Earnings Call

  • GlobeNewswire18 days ago

    Avinger Provides Fourth Quarter and Full Year 2018 Shareholder Update

    REDWOOD CITY, Calif., March 06, 2019 -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided,.

  • Benzinga18 days ago

    Avinger's Q4 Earnings Outlook

    On Wednesday, Mar. 6, Avinger (NASDAQ: AVGR ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Analysts are predicting Avinger will report a ...

  • ACCESSWIRE23 days ago

    Avinger to Present at Oppenheimer Healthcare Conference on March 20

    REDWOOD CITY, CA / ACCESSWIRE / March 1, 2019 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that Jeff ...

  • GlobeNewswire24 days ago

    Avinger to Announce Fourth Quarter and Full Year 2018 Financial Results on March 6, 2019

    Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2018 after the close of trading on Wednesday, March 6, 2019. Individuals interested in listening to the conference call may do so by dialing 877-407-9205 for domestic callers or +1-201-689-8054 for international callers. To listen to a live webcast, please visit http://www.avinger.com and select Investor Relations.

  • GlobeNewswire2 months ago

    Avinger’s Pantheris SV (Small Vessel) Featured in Live Case Transmission at Leipzig Interventional Course (LINC) 2019

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that its Pantheris® SV (Small Vessel) image-guided atherectomy system was featured in a live case transmission at Leipzig Interventional Course (LINC) 2019, a leading global forum for new methods and technology in the field of vascular medicine held annually in Leipzig, Germany. Pantheris SV is a product line extension of Avinger’s Lumivascular image-guided atherectomy system. Designed with a lower profile and longer length, Pantheris SV is intended to expand the addressable market for Pantheris, by allowing physicians to treat lesions in smaller vessels 2 to 4 millimeters in diameter.

  • Zacks.com featured highlights include: G-III, SP Plus, Penske Automotive, aTyr and Avinger
    Zacks2 months ago

    Zacks.com featured highlights include: G-III, SP Plus, Penske Automotive, aTyr and Avinger

    Zacks.com featured highlights include: G-III, SP Plus, Penske Automotive, aTyr and Avinger

  • What Bargain Hunting? Tap 5 Stocks With Rising P/E
    Zacks2 months ago

    What Bargain Hunting? Tap 5 Stocks With Rising P/E

    Bet on these top-ranked stocks with rising P/E to realize outsized gains.

  • 5 Top Rising P/E Stocks to Enjoy Solid Gains
    Zacks3 months ago

    5 Top Rising P/E Stocks to Enjoy Solid Gains

    Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of AVGR earnings conference call or presentation 13-Nov-18 9:30pm GMT

    Q3 2018 Avinger Inc Earnings Call

  • GlobeNewswire3 months ago

    Avinger Announces Preliminary Analysis of Results from SCAN Clinical Study

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the release of the preliminary analysis of results from its SCAN clinical study, a post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. Initial analysis of the SCAN data indicated that OCT imaging with Avinger’s Pantheris System showed statistical superiority or equivalence to IVUS on all parameters evaluated.

  • GlobeNewswire3 months ago

    Avinger Announces Successful Treatment of 500th Patient with Next-Generation Pantheris Device

    Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that physicians in 59 sites globally have successfully treated more than 500 patients with the next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD). The next-generation Pantheris was launched on a limited basis in the U.S. following receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) in late May 2018 and features a number of improvements intended to augment the performance and reliability of the product. Initial market uptake, acute clinical outcomes, and physician feedback validate that the design enhancements have driven adoption of the next generation device, as evidenced by a 38% year-over-year increase in Pantheris sales in the third quarter of 2018, its first full quarter following launch.

  • ACCESSWIRE4 months ago

    New Healthcare Trends Pushing Stocks Higher On Thursday

    CORAL GABLES, FL / ACCESSWIRE / December 6, 2018 / Analyst firms like Global Market Insights are expecting a lot as far as the future of healthcare is concerned. The firm reports that the healthcare industry ...

  • GlobeNewswire4 months ago

    Avinger Announces Commercial Launch in Australia

    Avinger, Inc. (AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the commercial launch of its Pantheris image-guided atherectomy system in Australia. Avinger recently completed an exclusive distribution agreement with Diverse Devices Pty Ltd. for the sales and marketing of Avinger’s proprietary Lumivascular products in Australia. In addition, the Company announced it has received notice from Australia’s Therapeutic Goods Administration (TGA) that the Pantheris image-guided atherectomy system has been included on the Australian Register of Therapeutic Goods, which permits distribution in Australia.

  • Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
    Zacks4 months ago

    Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals

    Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals

  • 5 Top-Ranked Rising P/E Stocks to Lure Investors
    Zacks4 months ago

    5 Top-Ranked Rising P/E Stocks to Lure Investors

    Inside the top-ranked stocks that have been exhibiting rising P/E ratios.

  • GlobeNewswire4 months ago

    Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE4 months ago

    Avinger Announces Successful Treatment of First Patients Globally with Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels

    REDWOOD CITY, CA / ACCESSWIRE / November 15, 2018 / Avinger, Inc. (AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the successful treatment of the first nine patients with Pantheris SV (Small Vessel) at two separate hospitals in Germany. Dr. Arne Schwindt, a vascular surgeon at St. Franziskus Hospital Muenster and longtime innovator with Lumivascular technology, performed the first procedures globally. Pantheris SV was used to successfully treat a variety of lesion types, including in-stent restenosis (ISR), calcified lesions, and a chronic total occlusion.

  • Associated Press4 months ago

    Avinger: 3Q Earnings Snapshot

    On a per-share basis, the Redwood City, California-based company said it had a loss of 56 cents. The medical device maker posted revenue of $2 million in the period. The company's shares closed at 31 cents. ...

  • ACCESSWIRE4 months ago

    Avinger Provides Third Quarter 2018 Shareholder Update

    REDWOOD CITY, CA / ACCESSWIRE / November 13, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system ...

  • ACCESSWIRE5 months ago

    Avinger to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2018

    REDWOOD CITY, CA / ACCESSWIRE / November 7, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that ...

  • ACCESSWIRE5 months ago

    Avinger to Announce Third Quarter 2018 Financial Results on November 13, 2018

    REDWOOD CITY, CA / ACCESSWIRE / November 5, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that ...

  • ACCESSWIRE5 months ago

    Avinger Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

    REDWOOD CITY, CA / ACCESSWIRE / November 1, 2018 / Avinger, Inc. (AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the closing of its previously announced underwritten public offering on November 1, 2018, with total gross proceeds of approximately $11.5 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Avinger. The offering is comprised of 3,535,000 Class A Units, priced at a public offering price of $0.40 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $0.40 per share, and 8,586 Class B Units, priced at a public offering price of $1,000 per unit, with each unit consisting of one share of Series C convertible preferred stock, having a conversion price of $0.40, and a five-year warrant to purchase 2,500 shares of common stock with an exercise price of $0.40 per share.

  • ACCESSWIRE5 months ago

    Avinger Announces Pricing of $10 Million Underwritten Public Offering

    REDWOOD CITY, CA / ACCESSWIRE / October 30, 2018 / Avinger, Inc. (AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the pricing of an underwritten public offering for gross proceeds of approximately $10 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Avinger. The offering is comprised of 3,535,000 Class A Units, priced at a public offering price of $0.40 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $0.40 per share, and 8,586 Class B Units, priced at a public offering price of $1,000 per unit, with each unit consisting of one share of Series C convertible preferred stock, having a conversion price of $0.40, and a five-year warrant to purchase 2,500 shares of common stock with an exercise price of $0.40 per share.

  • ACCESSWIRE5 months ago

    Avinger Receives CE Marking Approval for Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels

    REDWOOD CITY, CA / ACCESSWIRE / October 18, 2018 / Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced Conformité Européenne (CE) Marking approval of Pantheris SV (Small Vessel), a product line extension of the Lumivascular atherectomy system. CE Marking allows for distribution of Pantheris SV in the European Union (EU) and certain other countries that recognize the CE Marking. Pantheris SV is not available commercially in the United States at this time.